Immunotherapy in Melanoma | Specialty

The OncLive Immunotherapy in Melanoma condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in melanoma and other skin cancers. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.

Expert Says Melanoma Clinical Trials Should Include More Patients With Brain Mets

December 12th 2017

Harriet Kluger, MD, discussed the lack of clinical trial inclusion for patients with melanoma who have brain metastases, as well as promising regimens coming down the pike.

Dr. Sznol Discusses the Role of Surgery in Melanoma

December 8th 2017

Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses the role of surgery in the treatment of patients with melanoma.

Dr. Atkins Discusses the Adjuvant Treatment of Melanoma

December 8th 2017

Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses the adjuvant treatment of melanoma.

Dr. Postow Discusses Combination Therapy for Melanoma

December 6th 2017

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses combination therapy for patients with melanoma.

Ipilimumab Effective in Adolescents With Advanced Melanoma

November 30th 2017

Ipilimumab was associated with a 1-year overall survival rate of 75% in adolescent patients with stage III/IV unresectable malignant melanoma.

Dr. Atkinson on Novel Combinations in Melanoma

November 30th 2017

Victoria Atkinson, MD, medical oncologist, Princess Alexandra Hospital, University of Queensland, discusses novel combinations for the treatment of patients with melanoma.

Dr. Luke on the Clinical Trial Landscape for Melanoma

November 29th 2017

Jason Luke, MD, assistant professor of medicine at the University of Chicago Medicine, discusses the clinical trial landscape for melanoma

Dr. Soyer Discusses the Role of Technology in Melanoma

November 21st 2017

Peter Soyer, MD, academic dermatologist, professor, The University of Queensland Diamantina Institute, discusses the role of technology in melanoma.

The Future Role of PARP Inhibition in Ovarian Cancer

November 20th 2017

Combinations With PARP Inhibitors for Ovarian Cancer

November 20th 2017

Ovarian Cancer: Selecting an Appropriate PARP Inhibitor

November 20th 2017

Ovarian Cancer: Treating Through Multiple Progressions

November 20th 2017

Ovarian Cancer: Comparisons Between PARP Inhibitors

November 20th 2017

PARP Inhibitors's Role as Maintenance Therapy in EOC

November 20th 2017

Ovarian Cancer: Optimizing Treatment With Niraparib

November 20th 2017

Treating Ovarian Cancer With Niraparib: The NOVA Trial

November 20th 2017

Platinum-Sensitive Relapsed Ovarian Cancer: Rucaparib

November 20th 2017

Value of Olaparib in BRCA-Mutated Advanced Ovarian Cancer

November 20th 2017

PARP Inhibitors' Impact on Advanced Ovarian Cancer

November 20th 2017

Ovarian Cancer: Considerations for Molecular Testing

November 20th 2017